Nivalis Therapeutics Stock Shares Fall On Announcement
Warrior Trading | Nov 30, 2016 11:58PM ET
Nivalis Therapeutics Inc (NASDAQ:NVLS)
Nivalis Therapeutics, Inc. (NVLS), a clinical-stage pharmaceutical company yesterday announced their results for their phase 2 cystic fibrosis drug has failed. The study showed that the drug failed to reach its primary endpoints in the clinical trial.
h3 Nivalis Therapeutics, Inc. CEO’s Comments/h3“While we are disappointed in the outcome of this trial, we plan to continue to investigate the therapeutic potential of cavosonstat and our S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to determine next steps,” said Jon Congleton, president and chief executive officer of Nivalis. Globe Newswire
h3 NVLS Technical Analysis/h3NVLS opened trading yesterday at $6.32 which was up from the previous day’s trading close of $6.28. NVLS closed trading yesterday at $6.25 and crashed down after market to $2.95, equivalent to a 53% decrease from the closing price. Taking a look at the daily chart we can see that we are in unchartered territory as NVLS is now trading at all time lows Taking a closer look at the daily chart we can see that before the spike down NVLS had already been in an overall downward trend dating back to September 20th when it traded at $34.60. NVLS has a float of 6.93 million shares and traded below the normal daily trading volume on Monday. For trading purposes, I would like to see NVLS open trading on Tuesday below $4 and if it does I would be looking to take a short position at the bell. My stop loss would be $0.40 from my entry position fearing anything more than that and the stock would start to fill in the gap down. My friend Ross over at Warrior Trading is applying his Day Trading Strategies to these types of stocks.
Company Profile
Nivalis Therapeutics, Inc., incorporated on March 30, 2007, is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). The Company focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. The Company operates through discovering and development of potential drugs segment. The Company’s operations are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. GSNOR inhibitor portfolio includes other compounds with differing chemical structures and properties suitable for oral, inhaled, injectable and topical administration. Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company’s product candidate, N91115, is a small molecule compound that addresses a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) resulting from mutations in the CFTR gene, the underlying cause of CF. It has completed a Phase Ib clinical trial to evaluate the safety of N91115 in adult CF patients homozygous for F508del. The Company is conducting a Phase II clinical trial designed to demonstrate the safety of a triple therapy of N91115 along with lumacaftor/ivacaftor in over 130 adult CF patients homozygous for F508del. The N91115 development program is focused on demonstrating the clinical benefit of a triple CFTR modulator therapy for CF patients homozygous for F508del. The Company competes with Vertex Pharmaceuticals (NASDAQ:VRTX), Inc., PTC Therapeutics, Novartis AG (NYSE:NVS), Pfizer (NYSE:PFE), Galapagos, ProQR Therapeutics, Flatley Discovery Labs, Parion Sciences, Concert, Proteostasis, Calista, Shire, Gilead Sciences (NASDAQ:GILD), AbbVie Inc (NYSE:ABBV), AmpliPhi Biosciences and F. Hoffmann LaRoche.
Get The News You Want
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.